Type I interferons protect mice against enterovirus 71 infection

Area of Science:

• Virology
• Immunology
• Infectious Diseases

Background:

• Enterovirus 71 (EV71) is a significant human pathogen causing severe neurological diseases.
• The role of type I interferons (IFNs) in antiviral defense against EV71 remains incompletely understood.

Purpose of the Study:

• To investigate the contribution of type I IFNs to protection against EV71 infection in a murine model.
• To explore the therapeutic potential of modulating type I IFN responses for EV71 treatment.

Main Methods:

• Utilized a neonatal ICR mouse model for EV71 infection via intraperitoneal or oral routes.
• Administered dexamethasone, polyriboinosinic:polyribocytidylic acid [poly(I:C)], type I IFN-neutralizing antibodies, and recombinant mouse IFN-alphaA.
• Assessed clinical symptoms, tissue viral titers, survival rates, and immunological markers (serum IFN-alpha, dendritic cells, MHC class II).
• Performed in vitro analysis using human cell lines to evaluate direct IFN effects.

Main Results:

• Dexamethasone exacerbated EV71 infection, while poly(I:C) treatment improved survival and reduced viral load.
• Poly(I:C) administration correlated with increased serum IFN-alpha, enhanced dendritic cell function, and elevated splenic IFN-alpha.
• Neutralization of type I IFNs led to increased mortality and viral titers, whereas recombinant IFN-alphaA conferred protection.
• In vitro studies confirmed a direct protective effect of human type I IFNs against EV71.

Conclusions:

• Type I IFNs play a critical role in controlling EV71 infection and replication.
• Modulating type I IFN responses presents a potential therapeutic strategy against EV71.
• Understanding IFN-mediated immunity is key to developing effective treatments for enterovirus infections.